Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage

Hypertension

Volumn 59, Issue 1, 2012, Pages 136-144

  Zhang, Weiru ^a,b   Wang, Wei ^a,b   Yu, Hong ^d   Zhang, Yujin ^a   Dai, Yingbo ^e   Ning, Chen ^a,b   Tao, Lijian ^b   Sun, Hong ^a,c   Kellems, Rodney E ^a   Blackburn, Michael R ^a   Xia, Yang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Department of Nephrology ^*  (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d HUNAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^e CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

chronic kidney disease; cytokines; endothelin 1; hypertension; renin angiotensin system

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN 1; INTERLEUKIN 6; MESSENGER RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY INJURY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEINURIA;

ADULT; ANGIOTENSIN II; ANIMALS; BIOPSY; BLOOD PRESSURE; DISEASE PROGRESSION; ENDOTHELIN-1; FEMALE; FIBROSIS; HUMANS; HYPERTENSION, RENAL; INTERLEUKIN-6; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; VASOCONSTRICTOR AGENTS;

EID: 83655184758     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.173328     Document Type: Article

References (39)

1. Klahr S. Progression of chronic renal disease. Heart Dis. 2001;3: 205-209. (Pubitemid 33131475)
2. Khosla N, Kalaitzidis R, Bakris GL. The kidney, hypertension, and remaining challenges. Med Clin N Am. 2009;93:697-715, Table of Contents.
3. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: Implications for therapy. Hypertension. 2004;44:595-601. (Pubitemid 39435221)
4. Ritz E. Hypertension and kidney disease. Clin Nephrol. 2010;74(suppl 1):S39-S43.
5. Kuroki A, Akizawa T. Management of chronic kidney disease-preventing the progression of renal disease [in Japanese]. Nippon Rinsho. 2008;66: 1735-1740.
6. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease-what have we learned in 10 years? Semin Dial. 2010;23:498-509.
7. Nangaku M, Fujita T. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res. 2008;31:175-184. (Pubitemid 351461095)
8. Leoncini G, Viazzi F, Pontremoli R. Chronic kidney disease and albuminuria in arterial hypertension. Curr Hypertens Rep. 2010;12:335-341.
9. Horl WH. Hypertension in end-stage renal disease: different measures and their prognostic significance. Nephrol Dial Transplant. 2010;25: 3161-3166.
10. Campese VM, Park J. The kidney and hypertension: over 70 years of research. J Nephrol. 2006;19:691-698. (Pubitemid 46415971)
11. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85-97. (Pubitemid 47016250)
12. Hackam DG, Spence JD, Garg AX, Textor SC. Role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension. 2007;50:998-1003. (Pubitemid 350172917)
13. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Associations between circulating inflammatory markers and residual renal function in crf patients. Am J Kidney Dis. 2003;41:1212-1218. (Pubitemid 36637976)
14. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B. Serum albumin, c-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with esrd. Am J Kidney Dis. 2006;47: 139-148. (Pubitemid 41828276)
15. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant. 2003;18:1042-1045. (Pubitemid 36722500)
16. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in esrd: What is the role of interleukin-6? Kidney Int. 2002:103-108.
17. Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol. 2006;290:H935-H940.
18. Coles B, Fielding CA, Rose-John S, Scheller J, Jones SA, O'Donnell VB. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol. 2007;171:315-325. (Pubitemid 47339248)
19. Brands MW, Banes-Berceli AK, Inscho EW, Al-Azawi H, Allen AJ, Labazi H. Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension. 2010;56:879-884.
20. Crosswhite P, Sun Z. Ribonucleic acid interference knockdown of interleukin 6 attenuates cold-induced hypertension. Hypertension. 2010;55: 1484-1491.
21. Gadonski G, LaMarca BB, Sullivan E, Bennett W, Chandler D, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension. 2006;48:711-716. (Pubitemid 44843876)
22. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368: 339-342. (Pubitemid 24104268)
23. Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, Sun C, Ahmed A, Kellems RE, Xia Y. Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res. 2007;100:88-95. (Pubitemid 46074969)
24. Zhou CC, Irani RA, Zhang Y, Blackwell SC, Mi T, Wen J, Shelat H, Geng YJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-βinduction contributes to increased soluble endoglin production in preeclampsia. Circulation. 2010;121:436-444.
25. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14: 855-862.
26. Wolf G. Angiotensin II as a renal growth factor. Contrib Nephrol. 2001: 92-110.
27. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin ii-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52: 11-34. (Pubitemid 30127593)
28. Simonson M, Osanai T, Wann S, Baldi E, Mene P, Nakazato Y, Kester M, Thomas C, Dunn M. Effects of endothelin on cultured human and rat glomerular mesangial cells. Contrib Nephrol. 1991;95:1-11.
29. Simonson MS, Dunn MJ. Endothelin peptides: a possible role in glomerular inflammation. Lab Invest. 1991;64:1-4.
30. Khimji AK, Rockey DC. Endothelin: biology and disease. Cell Signal. 2010;22:1615-1625.
31. Kohan DE. Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens. 2010;19:134-139.
32. Suga S. Molecular biology in regulation of kidney functions: endothelin [in Japanese]. Nippon Rinsho. 2006;64(suppl 2):209-212.
33. Ge Y, Huang Y, Kohan DE. Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure. Can J Physiol Pharmacol. 2008;86:329-336. (Pubitemid 351821125)
34. Schiffrin EL. The angiotensin-endothelin relationship: does it play a role in cardiovascular and renal pathophysiology? J Hypertens. 2003;21: 2245-2247. (Pubitemid 38293561)
35. Grassl C, Luckow B, Schlondorff D, Dendorfer U. Transcriptional regulation of the interleukin-6 gene in mesangial cells. J Am Soc Nephrol. 1999;10:1466-1477. (Pubitemid 29297521)
36. Chen WP, Chen A, Lin CY. In vitro effects of interleukins on human mesangial cells: implications for glomerulonephritis. J Pathol. 1995;175: 327-337.
37. Coleman DL, Ruef C. Interleukin-6: an autocrine regulator of mesangial cell growth. Kidney Int. 1992;41:604-606.
38. Covic A, Gusbeth-Tatomir P. The role of the renin-angiotensin-aldosterone system in renal artery stenosis, renovascular hypertension, and ischemic nephropathy: diagnostic implications. Prog Cardiovasc Dis. 2009;52:204-208.
39. Benavente D, Chue CD, Ferro CJ. The importance of renin-angiotensin blockade in patients with cardio-renal disease. J Renal Care. 2010; 36(suppl 1):97-105.